Rein Therapeutics, Inc.
RNTX Nasdaq
SEC CIK 1420565
Follow Rein Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$5.5M
+0.8% vs same quarter last year
EPS, diluted
−$0.06
+71.4% vs same quarter last year
Operating cash flow
−$7.3M
−104.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$49.9M |
| FY24 | $0 | −$62.9M |
| FY23 | $0 | −$15.7M |
| FY22 | $0 | −$27.3M |
| FY21 | $0 | −$26.2M |
| FY20 | $0 | −$27.3M |
| FY19 | $0 | −$29.4M |
| FY18 | $0 | −$31.5M |
| FY17 | $0 | −$22.6M |
| FY16 | $0 | −$18.1M |
| FY15 | $0 | −$12.9M |
| FY14 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | −$23.9M |
| FY20 | −$20.5M |
| FY19 | −$26.6M |
| FY18 | −$32.3M |
| FY17 | −$20.7M |
| FY16 | - |
| FY15 | −$11.8M |
| FY14 | - |